Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2021 – AML
ASH 2021 – AML
Gilteritinib and Azacitidine versus Azacitidine for Newly Diagnosed FLT3-Mutated AML in Patients Ineligible for Intensive Induction Chemotherapy
ASH 2021 – AML
Gilteritinib plus azacitidine led to significantly higher composite complete remission rates but did not provide a survival advantage compared with azacitidine alone in patients with newly diagnosed
FLT3
mut+
AML ineligible for intensive induction chemotherapy.
Read More ›
Prognostic Value of MRD in AML Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation in First versus Second Morphologic Remission
ASH 2021 – AML
MRD status at the time of allogeneic stem-cell transplantation and the number of remissions prior to transplant were shown to be important independent prognostic factors in patients with AML.
Read More ›
First-in-Human Study of Menin Inhibitor SNDX-5613 in MLL-Rearranged and NPM1-Mutant Acute Leukemia
ASH 2021 – AML
In the first-in-human phase 1/2 AUGMENT 101 study, SNDX-5613 demonstrated an acceptable safety profile and promising antileukemic activity in patients with heavily pretreated relapsed/refractory
MLL
-rearranged and
NPM1
-mutated acute leukemias.
Read More ›
Allogeneic Stem-Cell Transplantation for Patients with AML in Second Complete Remission Transplanted from Unrelated Donors with Post-Transplant Cyclophosphamide
ASH 2021 – AML
AML patients who underwent allogeneic stem-cell transplantation from unrelated donors while in their second complete remission with post-transplant cyclophosphamide had similar outcomes to those who underwent transplantation while in first complete remission.
Read More ›
Ivosidenib plus Azacitidine versus Placebo plus Azacitidine in Patients with Newly Diagnosed AML with an IDH1 Mutation
ASH 2021 – AML
The phase 3 AGILE study demonstrated that ivosidenib + azacitidine therapy provided significant survival benefit compared with placebo plus azacitidine in patients with newly diagnosed
IDH1
mutation–positive AML who were ineligible for intensive chemotherapy.
Read More ›
Venetoclax plus FLAG-IDA Induction/Consolidation in Newly Diagnosed AML
ASH 2021 – AML
Addition of venetoclax to FLAG-IDA yielded high minimal residual disease–negative composite complete response rates in newly diagnosed patients with AML, accompanied by a favorable safety profile.
Read More ›
The FLT3/SYK Inhibitor HM43239 Shows Activity in Patients with Relapsed or Refractory FLT3-Mutated and Wild-Type AML
ASH 2021 – AML
Results from an ongoing first-in-human phase 1/2 study indicated that the FLT3/SYK inhibitor HM43239 yielded a favorable safety profile and encouraging antileukemic activity in patients with relapsed/refractory AML regardless of
FLT3
mutation status.
Read More ›
Hypomethylating Agent Therapy plus Venetoclax plus FLT3 Inhibitor Was Active in Older/Unfit Patients with FLT3-Mutated AML
ASH 2021 – AML
Findings from a retrospective analysis suggested that venetoclax plus hypomethylating agent plus an FLT3 inhibitor led to significant improvement in clinical outcomes, in older and unfit patients with
FLT3
-mutated AML.
Read More ›
Clinical Outcomes Based on Treatment Approach in Secondary AML with Prior Hypomethylating Agent Exposure
ASH 2021 – AML
Patients with treated secondary AML and prior hypomethylating exposure derived significant clinical benefit from hypomethylating agents plus venetoclax therapy compared with chemotherapy-based approaches.
Read More ›
Clinical Outcomes of Liposomal Daunorubicin/Cytarabine (CPX-351) versus HMA + Venetoclax As Frontline Therapy in Newly Diagnosed AML
ASH 2021 – AML
In a retrospective analysis, upfront liposomal daunorubicin/cytarabine treatment was shown to accord an overall survival advantage compared with HMA + venetoclax, which, however, did not extend to complete response rates and recurrence-free survival.
Read More ›
Page 1 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us